$RXRX · RECURSION PHARMACEUTICALS, INC. SEC Filings
Position Tracker tracks 2 SEC EDGAR filings for RECURSION PHARMACEUTICALS, INC. ($RXRX) from November 2, 2026 through November 2, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 1 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$RXRX 10-Q — RECURSION PHARMACEUTICALS, INC.
Recursion's 258% revenue growth and sharply narrower losses show its AI-drug-discovery model gaining traction, but the immediate post-quarter $187M dilutive raise tempers the bu…
$RXRX 8-K — RECURSION PHARMACEUTICALS, INC.
Recursion is delivering clinical validation across multiple wholly-owned programs while simultaneously monetizing its AI platform through Big Pharma partnerships — a dual-engine…